May 29th

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

New Data to be Presented at ASCO Shows Survival Benefit in Complete and Partial Responders Compared with Chemotherapy Alone

Genta Incorporated (OTC Bulletin Board: GNTA) announced the results of long-term followup from a Phase 3 trial of the Company\'s lead oncology product, Genasense(R) (oblimersen sodium) Injection, in patients with chronic lymphocytic leukemia (CLL). With 5 years of followup, new data show that patients who achieved either a complete response (CR -- the trial\'s primary endpoint) or a partial response (PR) have also achieved a statistically significant increase in overall survival. The data will be featured in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2008.
Read more: Genta Incorporated ( GNTA )
May 29th

Synthesis Energy Systems Strengthens Engineering Capabilities Through a Global Cooperation Agreement With China National Chemical Engineering Corporation

Synthesis Energy Systems, Inc. (\"SES\") (Nasdaq: SYMX) and China National Chemical Engineering Corporation (\"CNCEC\"), China\'s largest chemical engineering group and the country\'s leader in coal gasification and methanol plant construction, today announced the signing of a global cooperation agreement to work together on the engineering, design, procurement and construction of U-GAS(R) gasification projects worldwide. CNCEC is comprised of six chemical engineering companies and 13 construction companies throughout China with over 60,000 employees, and has completed more than 90% of China\'s chemical projects.

\"We are pleased to join forces with CNCEC to advance the capabilities of SES\' U-GAS(R) technology to provide clean, affordable alternative energy solutions from indigenous coal resources,\" said Tim Vail, SES\' President and CEO.
Read more: Synthesis Energy Systems Inc ( SYMX )
May 29th

Coastal Marina, LLC, a New York-Based Gaming Venture, to Acquire Trump Marina Hotel Casino from Trump Entertainment Resorts, Inc.

Coastal Marina, LLC, (“Coastal Marina”) an affiliate of Coastal Development, LLC, announced today that it has entered into an agreement to purchase the Trump Marina Hotel Casino in Atlantic City, New Jersey from Trump Entertainment Resorts, Inc. (NASDAQ: TRMP) (“Trump Entertainment Resorts”). Coastal Marina has agreed to pay Trump Entertainment Resorts $316 million to complete the transaction. As part of the transaction, the parties have also agreed to end prior, unrelated litigation, with prejudice, upon the closing of the transaction.

Upon successful acquisition of the property, Coastal Marina will re-brand and refurbish the property into a new destination resort under the “Margaritaville™” brand. Richard T. Fields, chairman of Coastal Marina, said: “Together with Jimmy Buffett’s team at Margaritaville™, our plans are to create an exciting new property that we believe will tap its full potential and make it one of the most successful destination gaming resorts in Atlantic City.
Read more: Trump Entertainment Resorts Inc ( TRMP )
Dayton Superior Corporation (NASDAQ: DSUP), the leading North American provider of specialized products for the non-residential concrete construction market, reported today the following results for its first quarter ended March 28, 2008, compared with results for the similar period of 2007:

* Net sales were $95 million, down from $99 million in 2007, primarily due to fewer good weather days;
* Gross profit decreased $1 million to $28 million, due to lower net sales;
* Net loss of $18 million, or 95 cents per share, as compared to $8 million, or 45 cents per share. Of the $18 million, $6 million is related to the refinancing of a portion of the Company’s debt.
Read more: Dayton Superior Corporation ( DSUP )
-Ultralife (NASDAQ: ULBI) announced that, based on a review of its progress for the second quarter ending June 28, the company expects to report revenue in excess of $75 million. These expected results compare to management’s previous guidance, which estimated revenue in the range of approximately $60 million to $70 million. For the full year 2008, the company now forecasts revenue of at least $250 million.

“The revenue increase is attributable to strong shipments to date, strong backlog in most businesses and requests from customers for accelerated deliveries against their orders,” said John D. Kavazanjian, Ultralife\'s president and chief executive officer. “We will provide more details about our second quarter performance and the outlook for the third quarter and full year when we report second quarter results, currently planned for July 31, 2008.”
Read more: Ultralife ( ULBI )